MARK L. WATSON
M.D., Ph.D., COO, Guardian Research Network
Mark Watson, M.D., Ph.D. joined the Guardian Research Network in 2013 as Chief Operating Officer, bringing more than 12 years of leadership and pharmaceutical industry experience. Dr. Watson was responsible for genomic and biomarker-guided new drug programs at Merck, Schering-Plough and GSK; incorporating scientific, regulatory and commercial strategies. His proposals on genomics and biomarkers in clinical research have been incorporated into FDA and global regulatory agencies such as CIOMS, and are now standard practice in clinical trials. Dr. Watson attended Duke Medical School and is a trained pathologist from University of Texas Southwestern Medical Center at Dallas, TX where he was an Assistant Professor and led an NIH-funded laboratory for over six years.
Re-engineering the US Clinical Trials System
It is quite ironic that nearly 800 cancer drugs are awaiting testing in clinical trials, yet there are hundreds of thousands of trial candidates available in the community where 85% of cancer patients are treated. To address this vexing problem, the Guardian Research Network (GRN)—a fully-integrated, electronic network of hospitals—has been established to radically increase trial accrual speed. The GRN aims to leverage >10% of the community to democratize clinical trial access and revolutionize drug development.